Land: Jordanien
Språk: engelska
Källa: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Ceftriaxone 250 mg
مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store
J01DD04
Ceftriaxone 250 mg
250 mg
1+2ml SOLV.
F.Hoffmann La- Roche (سويسرا)
6.92 :سعر الجمهور + الضريبة
February 2022 Product Information GCC Rocephin _ _ February 2022 Product Information GCC 1 ROCEPHIN ® Ceftriaxone COMPOSITION _Active ingredient:_ ceftriaxone (as the disodium salt). Rocephin contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone. PHARMACEUTICAL FORM AND ACTIVE SUBSTANCE QUANTITY PER UNIT _250 mg i.v. _ _Dry substance:_ ceftriaxone 250 mg as disodium ceftriaxone per vial. _Solvent:_ water for injection 5 ml. _250 mg i.m. _ _Dry substance:_ ceftriaxone 250 mg as disodium ceftriaxone per vial. _Solvent:_ lidocaine hydrochloride 20 mg, water q.s. 2 ml of solution. _500 mg i.v. _ _Dry substance:_ ceftriaxone 500 mg as disodium ceftriaxone per vial. _Solvent:_ water for injection 5 ml. _500 mg i.m. _ _Dry substance:_ ceftriaxone 500 mg as disodium ceftriaxone per vial. _Solvent:_ lidocaine hydrochloride 20 mg, water q.s. 2 ml of solution. _1 g i.v. _ _Dry substance:_ ceftriaxone 1 g as disodium ceftriaxone per vial. _Solvent:_ water for injection 10 ml. _1 g i.m. _ _Dry substance:_ ceftriaxone 1 g as disodium ceftriaxone per vial. _Solvent:_ lidocaine hydrochloride 35 mg, water q.s. 3.5 ml of solution. _2 g i.v. _ _Dry substance:_ ceftriaxone 2 g as disodium ceftriaxone per vial. INDICATIONS/USES Infections caused by pathogens sensitive to ceftriaxone, e.g.: - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - renal and urinary tract infections; - genital infections, including gonorrhoea; - sepsis; February 2022 Product Information GCC Rocephin _ _ February 2022 Product Information GCC 2 - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired immunity; - meningitis; - disseminated Lyme borreliosis (stages II and III). Perioperative prophylaxis of infections associated with gastrointestinal, biliary , urogenital, gynaecological surgery, but only in cases of potential or definite contamination. Officia Läs hela dokumentet